17,261 trials
Rosacea
Primary: Investigator Global Assessment (IGA) 0=Clear, 1=Near Clear, 2=Mild, 3=Moderate, 4=Severe — 35; 15; 16; 6 Participants
Hypertension, Pulmonary
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) — 0.936; 0.885; 0.813; 1.017 Ratio
Asthma · Inflammation
Primary: Number of Acute Exacerbation at 3 Months — 2.7; 2.2; 1.6; 2.2 Events — p=0.78
Recurrent Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma
Primary: Overall Response After 3 Cycles of Botezomib Plus ICE (BICE) Versus Ifosfamide, Carboplatin, Etoposide (ICE) in Patients With Relapsed/Refractory Classical Hodgkin…
Duchenne Muscular Dystrophy
Primary: Mean Change From Baseline to 24 Weeks in the 6-minute Walk Distance (6MWD) — -3.5; -7.5; -17.0 meter
Itch
Primary: Absolute NRS Itch Score at Week 16 (End of Treatment) — 7; 7.5 Units on a scale
Pregnant Women
Primary: Success of Anesthesia — 4; 4; 4; 1 Participants
Refractory Multiple Myeloma
Primary: Find Maximum Tolerated Dose (MTD) of Bortezomib in Combination With Pomalidomide and Dexamethasone Out to 2.5 Years, by Count of Patients With Dose Limiting Toxicities…
Metabolism and Nutrition Disorder · Obesity
Primary: Relative Change in Body Weight (%) — -5.99; -8.62; -11.60; -11.17 Percentage (%) of body weight — p==0.0055
Graft Versus Host Disease
Primary: GVHD-free Survival Rate — 33.3 percentage of patients
Chronic Ischemic Stroke
Primary: Proportion of Subjects Whose Fugl-Meyer Motor Total Score (FMMS) Improved by ≥ 10 Points at Month 6 From Baseline — 7; 9; 7; 46 Participants — p=0.6743
Acute Myeloid Leukemia
Primary: Part 1: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
Diabetes Mellitus, Type 2 · Hypertension
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to TEAEs — 3; 3; 2; 4 Participants
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants
Hematological Malignancy
Primary: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 1; 0; 0 Participants